MEA112997 Open-label Long Term Extension Safety Study of Mepolizumab in Asthmatic Subjects
Completed · Phase 3
Conditions studied: Asthma
In brief
This is a multi-centre, open-label long term safety study of 100 milligrams (mg) mepolizumab administered subcutaneously (SC) in addition to standard of care in subjects who participated in the MEA112997 study. At each clinic visit, adverse events will be assessed and exacerbations will also be reviewed.
Key facts
- Study ID
- NCT01691859
- Run by
- GlaxoSmithKline
- People needed
- 347
- Starts
- 2012-09-28
- Expected to finish
- 2017-05-31
- Last updated by the study team
- 2023-06-28
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Informed Consent.
- MEA112997 Study Participation: Received at least 2 doses of double-blind investigational product during the MEA112997 trial.
- MEA112997 Treatment Assignment: If the subject received mepolizumab, they must have had a positive risk: benefit ratio.
- Currently being treated with a controller medication and the subject has been on a controller medication for the past 12 weeks.
- Male or Eligible Female Subjects. To be eligible for entry into the study, females of childbearing potential must commit to consistent and correct use of an acceptable method of birth control for the duration of the trial and for 4 months after the last study drug administration.
You may not qualify if…
- Hypersensitivity related to mepolizumab.
- Clinically significant change in health status since completing participation in the MEA112997 trial.
- A current malignancy or previous history of cancer in remission for less than 12 months prior to screening.
- For those subjects who had a SAE in MEA112997 that was assessed as possibly related to mepolizumab by the investigator.
- Subjects who are pregnant or breastfeeding. Subjects should not be enrolled if they plan to become pregnant during the time of study participation.
- Screening ECG which has a clinically significant abnormality.
- Received Xolair (omalizumab) within the past 130 days.
- Participated in a clinical trial within the past 30 days or have received investigational medication within five terminal half-lives of Screen Visit, whichever is longer.
- Current smokers.
Where it is running
- GSK Investigational Site — Riverside, California, United States
- GSK Investigational Site — Denver, Colorado, United States
- GSK Investigational Site — New Haven, Connecticut, United States
- GSK Investigational Site — Albany, Georgia, United States
- GSK Investigational Site — Lexington, Kentucky, United States
- GSK Investigational Site — Winston-Salem, North Carolina, United States
- GSK Investigational Site — Cleveland, Ohio, United States
- GSK Investigational Site — Hershey, Pennsylvania, United States
- GSK Investigational Site — Pittsburgh, Pennsylvania, United States
- GSK Investigational Site — Nashville, Tennessee, United States
- GSK Investigational Site — Mar del Plata, Buenos Aires, Argentina
- GSK Investigational Site — Buenos Aires, Argentina
- GSK Investigational Site — Buenos Aires, Argentina
- GSK Investigational Site — Mendoza, Argentina
- GSK Investigational Site — New Lambton, New South Wales, Australia
- GSK Investigational Site — Adelaide, South Australia, Australia
- GSK Investigational Site — Clayton, Victoria, Australia
- GSK Investigational Site — Melbourne, Victoria, Australia
- GSK Investigational Site — Nedlands, Western Australia, Australia
- GSK Investigational Site — Calgary, Alberta, Canada
- GSK Investigational Site — Vancouver, British Columbia, Canada
- GSK Investigational Site — Mississauga, Ontario, Canada
- GSK Investigational Site — Québec, Quebec, Canada
- GSK Investigational Site — Puente Alto - Santiago, Región Metro de Santiago, Chile
- GSK Investigational Site — Long Beach, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.